Compare ASE Technology Holding Co Ltd (ASX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs Regeneron Pharmaceuticals Inc — how do they compare? ASE Technology Holding Co Ltd trades at $38.85 (market cap $101.68B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: ASE Technology Holding Co Ltd is the larger of the two by market cap, and ASE Technology Holding Co Ltd pays the higher dividend (1.11%). Which is the better fit depends on your goals.
| ASX | REGN | |
|---|---|---|
Market Cap | $101.68B | $83.19B |
Sector | Technology | Health |
52-Week High | $45.12 | $812.27 |
52-Week Low | $9.63 | $555.51 |
Enterprise Value | $106.08B | $77.90B |
Dividend Yield | 1.11% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $37.39, up 0.38% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.29, beating estimates of $0.23, and announced a $10.5 billion capital expenditure increase for AI-driven growth (Reuters, July 30, 2026). Revenue rose to $645.39 billion in 2025, with net income of $40.02 billion, while valuation ratios like P/E of 46.26 suggest premium pricing.
Outlook remains positive due to AI semiconductor demand and margin expansion, but risks include high valuation and competitive pressures. Analysts are largely bullish with 80% buy ratings, though the stock faces volatility near resistance at $38.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
